Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Actinogen Medical ( (AU:ACW) ) has shared an update.
Actinogen Medical Limited has announced the quotation of 1,078,721 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of December 1, 2025. This move is part of the company’s strategic efforts to enhance its capital structure and support ongoing research and development activities, potentially strengthening its position in the biotechnology sector.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited operates in the biotechnology industry, focusing on the development of innovative therapies for neurological and neurodegenerative diseases. The company is primarily engaged in advancing its lead compound, Xanamem, which targets cognitive impairment associated with chronic neurological conditions.
YTD Price Performance: 140.0%
Average Trading Volume: 3,961,444
Technical Sentiment Signal: Buy
Current Market Cap: A$190.9M
See more insights into ACW stock on TipRanks’ Stock Analysis page.